Dianthus Therapeutics DNTH Deferred income
Deferred income at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's deferred income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Dianthus Therapeutics's deferred income?
- Dianthus Therapeutics (DNTH) reported deferred income of $1.49M in Q1 2026.
- How has Dianthus Therapeutics's deferred income changed year-over-year?
- Dianthus Therapeutics's deferred income increased by 210.0% year-over-year, from $479K to $1.49M.
- What is the long-term trend for Dianthus Therapeutics's deferred income?
- Over 3 years (2022 to 2025), Dianthus Therapeutics's deferred income has grown at a 128.2% compound annual growth rate (CAGR), from $100K to $1.19M.